Please ensure Javascript is enabled for purposes of website accessibility

Here's Why TG Therapeutics Rose as Much as 36.7% Today

By Maxx Chatsko - Dec 9, 2019 at 2:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A triple-combination therapy from the company triggered responses in 100% of patients with difficult-to-treat blood cancers.

What happened

Shares of TG Therapeutics (TGTX -10.56%) gained as much as 36.7% after the company announced an update for two triple-combination therapies it's developing as treatments for relapsed/refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). The clinical-stage company presented the data at the Annual Meeting of the American Society of Hematology (ASH).

Both triple combinations provoked robust responses in the difficult-to-treat cancers. In fact, one achieved an objective response rate (ORR) of 100%, which means all patients responded to treatment. The results are early and from a small number of patients, but they sure are promising.

As of 1:38 p.m. EST, the pharma stock had settled to a 24% gain.

An arrow bouncing up shelves on the wall.

Image source: Getty Images.

So what

The first triple-combination therapy includes ublituximab (an experimental monoclonal antibody), umbralisib (an experimental small-molecule inhibitor of PI3K delta and CK1 epsilon, two proteins involved in cellular growth), and venetoclax (an approved treatment for CLL). TG Therapeutics owns the first two assets and refers to the duo as U2. 

The triple-combination therapy achieved an ORR of 100% in 13 patients with CLL. Of the nine patients available for evaluation at the 12-month cutoff date, all achieved undetectable levels of minimal residual disease (MRD) in their blood, and seven (78%) had undetectable levels of MRD in their bone marrow. All have stopped treatment.

The second triple-combination therapy includes U2 and TG-1701, a once-daily BTK inhibitor. All three molecules are owned by TG Therapeutics. The proprietary triple combo achieved an ORR of 86% in seven patients with either relapsed/refractory CLL and NHL. While that sounds a little less impressive after reading about the perfect ORR above, the results are from the lowest dose of the BTK inhibitor that will be studied. However, BTK inhibitors can trigger mutations that make tumors resistant to treatment.

Now what

TG Therapeutics ended September with only $72.4 million in cash, which means investors might expect the company to wisely take advantage of a soaring stock price with a public stock offering. That would raise much-needed cash to support research and development efforts that include 10 clinical programs. Given the promising results from the two triple-combination therapies being developed, investors might not mind the dilution if the pipeline keeps delivering.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TG Therapeutics Stock Quote
TG Therapeutics
$6.10 (-10.56%) $0.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.